Oncotarget

Research Papers:

Expression characteristic of CXCR1 in different breast tissues and the relevance between its expression and efficacy of neo-adjuvant chemotherapy in breast cancer

Miao-Qun Xue, Jun Liu, Jian-Feng Sang, Lei Su and Yong-Zhong Yao _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:48930-48937. https://doi.org/10.18632/oncotarget.16893

Metrics: PDF 924 views  |   HTML 1386 views  |   ?  


Abstract

Miao-Qun Xue1, Jun Liu2, Jian-Feng Sang1, Lei Su1 and Yong-Zhong Yao1

1Department of General Surgery, Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China

2Department of General Surgery, The Jiang Bei People’s Hospital of Nanjing, Nanjing 210048, China

Correspondence to:

Yong-Zhong Yao, email: cnyongzhongyao321@yeah.net

Keywords: breast cancer, breast cancer stem cells, chemokine receptor, CXCR1, neo-adjuvant chemotherapy

Received: October 12, 2016     Accepted: February 22, 2017     Published: April 06, 2017

ABSTRACT

Objective: To investigate chemokine receptor CXCR1 expression characteristic in different breast tissues and analyze the relationship between CXCR1 expression changes in breast cancer tissue and efficacy of neo-adjuvant chemotherapy.

Results: Chemokine receptor CXCR1 was lowly expressed in normal breast tissues and breast fibroadenoma, but highly expressed in breast cancer. It was significantly correlated with pathological stage, tumor cell differentiation, and lymph node metastasis (P < 0.05). After neo-adjuvant chemotherapy, CXCR1 expression in breast cancer tissues decreased. Among these 104 breast cancer patients with different molecular subtypes, the survival rate with Luminal A was the highest, followed by the Luminal B breast cancer, TNBC was the worst.

Materials and Methods: 104 cases with breast carcinoma, 20 cases with normal breast and 20 cases with breast fibroadenoma were included and followed up. Immunohistochemistry was used to detect the expression of CXCR1 in the various tissues. The relationship between the CXCR1 expression changes in breast cancer biopsies and surgical specimens, as well as the efficacy of neo-adjuvant chemotherapy, was analyzed.

Conclusions: Chemokine receptor CXCR1 could be used as an indicator to predict benign or malignant breast disease, and it can even predict the malignancy degree of breast cancer, as well as its invasive ability and prognosis.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 16893